Group items matching

in title, tags, annotations or url

This Funding Opportunity Announcement (FOA) invites research grant applications from organizations/institutions that propose the development of novel radioligands for positron emission tomography (PET) or single photon emission computed tomography (SPECT) imaging in human brain, and that incorporate pilot or clinical feasibility evaluation in pre-clinical studies, model development, or clinical studies.

The purpose of this funding opportunity announcement (FOA) is to provide infrastructure support to advance development of operational definitions and approaches for the study of the concepts of cognitive reserve and resilience to Alzheimer's disease and related dementias (ADRD) and age-related cognitive decline. The infrastructure support will facilitate a collaborative research network through meetings, conferences, small-scale pilots, and dissemination activities to foster development and champion use of state-of-the-art definitions, uniform nomenclature, and validated approaches that will be key to the advancement of research on maintenance of brain and cognitive health and treatment and/or prevention of ADRD.

The purpose of this Funding Opportunity Announcement (FOA) is to elucidate the etiology and pathogenesis of the neurocognitive complications associated with type 2 diabetes (T2D) with the ultimate goal of informing future strategies to mitigate the risk of these complications. Applications should propose expansions of ongoing human studies of well characterized T2D cohorts or cohorts comparing T2D with non-diabetic populations.  Such expansions might include the addition of comprehensive neurocognitive measures (e.g., cognitive testing, neuroimaging, and biomarkers), clinical measures (e.g., insulin resistance, HbA1c), and/or collection of data on other risk factors (e.g., diet, obesity, micro- and macro-vascular disease, inflammation). It must be clearly explained how the collection of additional data will contribute to elucidation of the basis of neurocognitive sequelae of T2D.

The goal of this funding opportunity announcement (FOA) is to facilitate research to identify individual influences on the effectiveness of population-level strategies that target cancer-related behaviors. We seek to encourage collaborations among scientists with expertise in health policy research and implementation, as well as investigators in scientific disciplines that have not traditionally conducted cancer or policy research, such as: psychological science (e.g., social, developmental); affective and cognitive neuroscience; judgment and decision-making; consumer behavior and marketing; organizational behavior; sociology, cultural anthropology; behavioral economics; linguistics; and political science.

The PH/TBIRP was established by Congress in FY07 in response to the devastating impact of traumatic brain injury (TBI) and psychological health (PH) issues, including post-traumatic stress disorder (PTSD), on our deployed Service members (SMs) in Iraq and Afghanistan. The PH/TBIRP mission is to establish, fund, and integrate both individual and multiagency research efforts that will lead to improved prevention, detection, and treatment of PH issues and TBI. The vision of the PH/TBIRP is to prevent, mitigate, and treat the effects of traumatic stress and TBI on function, wellness, and overall quality of life for SMs as well as their caregivers and families.

The purpose of this Funding Opportunity Announcement (FOA) is to encourage cooperative agreement (U54) applications from multidisciplinary groups of investigators to accelerate the rate of progress in determining the functional, pharmacological, neuronal network and whole animal consequences of genetic variants discovered in patients with various types of epilepsy and to develop strategies for establishing diagnostic criteria and identifying potential targets for intervention.

To foster innovative collaborative approaches to research projects that propose novel pairings of investigators from at least two broadly disparate disciplines. The proposal must focus on the collaborative relationship, such that the scientific objectives could not be achieved without the efforts of at least two co-principal investigators and their respective disciplines. The combination and integration of studies may be inclusive of basic, clinical, population, behavioral, and/or translational research. Projects must include at least one Co-PI from a field outside cardiovascular disease and stroke. This award is also intended to foster collaboration between established and early- or mid-career investigators. Applications by existing collaborators are permitted, provided that the proposal is for a new and novel idea or approach that has not been funded before. Multidisciplinary research broadly related to cardiovascular function, cardiovascular disease, and stroke, or to related clinical, basic science, bioengineering, biotechnology, or public health problems. Proposals are encouraged from all basic science disciplines as well as epidemiological, behavioral, community and clinical investigations that bear on cardiovascular and stroke problems. AHA awards are open to the array of academic and health professionals. This includes but is not limited to all academic disciplines (biology, chemistry, engineering, mathematics, technology, physics, etc.) and all health-related professions (physicians, nurses, advanced practice nurses, pharmacists, dentists, physical and occupational therapists, statisticians, nutritionists, behavioral scientists, health attorneys, engineers, etc.).

The goal of this funding opportunity announcement is to continue and expand the open-science, systems-biology enterprise of the AMP-AD Target Discovery and Preclinical Validation Consortium and enable data-driven discovery and validation of novel targets and biomarkers for AD and AD-related dementias through the development of predictive network models of brain health and disease.

The goal of this funding opportunity announcement is to solicit applications focused on 1) providing data enablement for the open-science, systems-biology enterprise of the AMP-AD Target Discovery and Preclinical Validation Consortium supported through the companion FOA (RFA-AG-18-013) and 2) sustaining and expanding the big-data infrastructure of the AMP-AD Knowledge Portal as a collaborative research platform through which members of the Consortium, researchers at large, and citizen scientists can engage in rapid translational learning and contribute to the development of predictive models of AD and AD-related dementias.

This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to establish Centers of collaborating investigators with the goal of identifying and advancing research opportunities for translating immunotherapy concepts for children and adolescents with cancer toward clinical applications. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Recommendation (B) that calls for the establishment of a pediatric immunotherapy translational science network. The network was envisioned by the BRP as focusing on identifying new targets for immunotherapies, developing new pediatric immunotherapy treatment approaches (e.g., cancer vaccines, cellular therapy, combinations of immunotherapy agents, and others), and defining the biological mechanisms by which pediatric tumors evade the immune system. The Pediatric Immunotherapy Discovery and Development Network (PI-DDN) Centers will address and implement these BRP recommendations.

This Funding Opportunity Announcement (FOA) encourages applications that develop and test multilevel interventions to improve follow-up to abnormal screening tests for breast, cervical, colorectal, or lung cancers. Improving follow-up to abnormal screening tests is dependent on factors at the patient, provider, clinical team, clinic, healthcare institution, or community setting levels. Appropriate applications for this FOA should propose to intervene at two or more levels, and measure outcomes at three or more levels, while accounting for interactions that occur between and across levels.

Applicants for the funds may be students or faculty. The project, program, or entrepreneurial idea must be created by, led by or benefit women. Grants are awarded in values of $2500 to $20,000. While we prefer the base grant to be $5,000, we are considering a limited number of $2500 which will be required to show high impact. These applicants will be considered on a case-by-case basis. The grants must be submitted online via the link below and must include a 2-minute video. Applicants will be narrowed to a pool of 10-15 finalists by our M.I.A.M.I. WOMEN Grants Committee. This committee will review applications; contact applicants if additional information is required, and present the finalists to the M.I.A.M.I. WOMEN Steering Committee and Development Staff. Grant deadline for this year is Feb. 9, 2018. These finalists will perform in a fast-pitch style Hawk Tank event on April 11, 2018. Finalists will be offered fast-pitch training courtesy of the Farmers School of Business - school of Entrepreneurship, and will receive coaching and support. They will then pitch their idea in 5 minutes or less on April 11, 2018 at the event. Giving Circle members are the voters who will determine winners. Absentee voters will be given the option to vote online. Winners will be announced that night or the next day at the Symposium, to be determined.

The goal of this Funding Opportunity Announcement (FOA) is to stimulate research addressing Fundamental questions in basic neuroscience. Proposed projects can address any area of neuroscience within the missions of the participating institutes and should focus on understanding the development, the structure and/or the function of the normal nervous system. While Fundamental basic research often generates insights relevant to disorders of the nervous system, this FOA is not intended to stimulate research that is explicitly disease-related.

The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications that propose either basic, clinical, or a combination of basic and clinical studies to investigate how functional changes in the sensory and/or motor systems impact the development and progression of Alzheimer's disease. Studies may include older adults and/or animal models and may employ a variety of approaches, including cellular, molecular, imaging, physiological and genetic, to address this need. For clinical studies, leveraging of existing longitudinal cohorts already collecting sensory and motor assessments is highly encouraged.

The purpose of this funding opportunity announcement (FOA) is to support clinical studies that will fill gaps in the design of upcoming clinical trials in rare neurological or neuromuscular diseases by validating clinical outcome measures or biomarkers, or by characterizing cohorts of relevant patients. Through the support of trial readiness studies, NINDS expects to accelerate the initiation of clinical trials for rare diseases and to increase the likelihood of success in those trials.

This funding opportunity (FOA) encourages small business technology transfer STTR research and development of commercial pharmaceutical interventions to extend lifespan and/or healthspan, to prevent, treat, and/or slow the progression of symptoms associated with Alzheimer's disease (AD) or Alzheimer's disease related dementia (ADRD) in human cells and/or tissue, in-vitro models, and/or non-human animals.

This FOA encourages applications for exploratory clinical trials of investigational agents (drugs, biologics, surgical therapies or devices) that may contribute to the justification for and provide the data required for designing a future trial, for biomarker validation studies, or for proof of mechanism clinical studies. Diseases chosen for study should be based on the NINDS' strategic plan and clinical research interests (www.ninds.nih.gov/funding/areas/index.htm). Successful applicants will be given access to the NeuroNEXT infrastructure. Following peer review, NINDS will prioritize and order trials that are given access to the NeuroNEXT infrastructure. The NeuroNEXT Clinical Coordinating Center (CCC) will work with the successful applicant to efficiently implement the proposed study. The NeuroNEXT Data Coordinating Center (DCC) will provide statistical and data management support. The NeuroNEXT clinical sites will provide recruitment/retention support as well as on-site implementation of the clinical protocol.

This Funding Opportunity Announcement (FOA) invites innovative research focused on understanding the consequences of amyloid protein polymorphism in regulation and initiation of early pathogenesis in Alzheimer's disease (AD). Specifically, this FOA encourages collaborative approaches designed to identify and characterize the regulation of biochemical and cellular pathways that are responsible for the differential accumulation of various protein conformers in AD clinical subtypes.

This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to promote research that results in a comprehensive view of the dynamic, multidimensional tumor ecosystem. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Generation of Human Tumor Atlases. For the purposes of this FOA, a human pre-cancer atlas is defined as a multidimensional cellular, morphological and molecular mapping of human pre-malignant tumors, complemented with critical spatial information (at cellular and/or molecular level) that facilitate visualization of the structure, composition, and multiscale interactions within the tumor ecosystem over time resulting in progression or regression of the tumors.

A rich body of evidence suggests that optimal cognitive, affective, and social processes are associated with highly coordinated neural activity.  These findings suggest that oscillatory rhythms, their co-modulation across frequency bands, spike-phase correlations, spike population dynamics, and other patterns might be useful drivers of therapeutic development for treatment of cognitive, social, or affective symptoms in neuropsychiatric disorders. This funding opportunity supports projects that test whether modifying electrophysiological patterns during behavior can improve cognitive, affective, or social processing.